Eli Lilly & Co (NYSE:LLY) (Trend Analysis) shares were traded with a significant increase in volume. The stock closed last trading session at $78.34, up by 0.59%, with a volume of 6,903,501 shares against an average amount for the last three months of 3,692,180.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Eli Lilly & Co (NYSE:LLY) stock is currently trading 11.14% below its 52-week-high, 15.41% above its 52-week-low. The 1-year stock price history is in the range of $67.88 – $88.16. Eli Lilly & Co (LLY) has a price to earnings ratio of 34.08 versus Healthcare sector average of 40.79. LLY stock price has underperformed the S&P 500 by 12.9%. The Medical Drugs company is currently valued at $82.86 billion, and its share price closed the last trading session at $78.34. The stock has a 50-day moving average of $78.4 and a 200-day moving average of $77.96.
Eli Lilly & Co (LLY) current short interest stands at 8.57 million shares. It has increased by 24% from the same period of last month. Around 1% of the company’s shares, which are float, are short sold. With a 10-days average volume of 4.95 million shares, the number of days required to cover the short positions stand at 1.8 days.
LLY is forecasted to report earnings per share of $0.99 and a revenue of $5.55 billion for the 4th Quarter of the fiscal year 2016. Eli Lilly & Co (LLY) declared last quarter earnings on October 25. The Medical Drugs company announced last quarter earnings per share of $0.88 against a consensus Street estimate of $0.96, missing estimate by $0.08. The company posted a revenue of $5.19 billion compared to an estimation of $5.36 billion.
Is this a Trading Opportunity? Click here for a free Trend Analysis Report
There are currently twenty-four analysts that cover Eli Lilly & Co stock. Of those twenty-four, nineteen have a Buy rating, five have a Hold rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $96.55.
A recent analyst activity consisted of Jefferies reiterating their Buy stance on October 27. Jefferies decreased price target from $105 to $100. This corresponds to a 27.65% upside from the last closing price. On the date of report, the stock closed at $76.16.BMO Capital reiterated their Outperform stance on October 3. On the date of report, the stock closed at $81.
Another research firm was Goldman Sachs who upgraded their Neutral rating to Buy on September 27. Goldman Sachs increased their price target on Eli Lilly & Co from $89 to $95. This translates to a 21.27% upside from the last closing price. On the date of report, the stock closed at $80.88.Company snapshot
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.